Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Cybin IRL Limited
Single and Repeat Doses of DMT in Healthy Subjects
Algernon Pharmaceuticals
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital
Dance Movement Therapy for Radio-oncological Patients
University of Erlangen-Nürnberg Medical School
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)
University Hospital, Basel, Switzerland
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Bristol-Myers Squibb
A Trial of GH001 in Patients With Treatment-resistant Depression
GH Research Ireland Limited
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
Reconnect Labs
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
Novartis
The 'Wearing Off' Effect of DMT
Novartis Pharmaceuticals
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
Usona Institute
Safety and Pharmacokinetics of GH002 in Healthy Volunteers
GH Research Ireland Limited
SPL026 With or Without SSRIs in Participants With MDD
Small Pharma Ltd
Acute Dose-dependent Effects of DMT in Healthy Subjects
University Hospital, Basel, Switzerland
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
Beckley Psytech Limited
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
Novartis Pharmaceuticals
Pharmacokinetics of GH001 in Healthy Volunteers
GH Research Ireland Limited
Effects of Dimethyltryptamine in Healthy Subjects
University Hospital, Basel, Switzerland
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
University of Colorado, Denver
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
Small Pharma Ltd
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
Psychiatric University Hospital, Zurich
Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)
Delphinus Medical Technologies, Inc.
Clinical Study of GH001 in Depression
GH Research Ireland Limited
Prospective Stratification of Infectious Risks in Multiple Sclerosis
University Hospital, Basel, Switzerland
Safety of GH001 in Healthy Volunteers
GH Research Ireland Limited
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
University Hospital, Caen
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Hoffmann-La Roche
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Genentech, Inc.
Tecfidera and the Gut Microbiota
Biogen
Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy (D/MT) Program for Older Adults
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
Merck KGaA, Darmstadt, Germany
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Novartis Pharmaceuticals
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals
Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study
University of Utah
The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause
University Health Network, Toronto
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
University Hospital, Strasbourg, France
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants
University Hospital, Basel, Switzerland
Antidepressant Response of DMT Masked With Propofol
University Hospital, Basel, Switzerland
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
Yale University
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Deepak C. D'Souza
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
GH Research Ireland Limited
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
University of Rochester
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
GH Research Ireland Limited
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.